Gábor is Partner at NLC Health Ventures – the confounding entity of Karla – and CEO of SERDA Therapeutics. In his most recent endeavour, he was the CEO of a speciality biopharmaceutical company, Tavanta Therapeutics. Under Gábor’s guidance, Tavanta secured over $55 million in funding and grew from a 2-person company to an organisation with 5 pivotal clinical stage compounds for major indications such as oncology and pain, as well as an innovative pre-clinical pipeline following closely in their footsteps.
